Top

Diabetologia

Published in:

01-09-2009 | Article

Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus

Authors: L. Ye, K. O. Lee, L. P. Su, W. C. Toh, H. K. Haider, P. K. Law, W. Zhang, S. P. Chan, E. K. W. Sim

Published in: Diabetologia | Issue 9/2009

Abstract

Aims/hypothesis

We aimed to demonstrate the feasibility and efficacy of intra-muscular transplantation of human skeletal myoblasts (hSkMs) for attenuation of hyperglycaemia and improvement of insulin sensitivity using a mouse model of type 2 diabetes mellitus.

Methods

KK Cg-Ay/J mice, aged 12 to 14 weeks, underwent an initial intraperitoneal glucose tolerance test (GTT) and were divided into the following groups: KK control group, basal medium (M199) only; KK myoblast group, with hSkM transplantation; KK fibroblast group, with human fibroblast transplantation. Non-diabetic C57BL mice were used as an additional normal control and also had hSkM transplantation. Cells were transplanted intra-muscularly into the skeletal muscles of the mice. All animals were treated with ciclosporin for 6 weeks only. HbA_1c and fasting GTT, as well as serum adiponectin, cholesterol, insulin and triacylglycerol were studied.

Results

Immunohistochemistry studies showed extensive survival of the transplanted hSkMs in the skeletal muscles at 12 weeks, with nuclei of the hSkMs integrated into the host muscle fibres. Repeat GTT showed a significant decrease in glucose concentrations in the KK myoblast group compared with the KK control and KK fibroblast groups. The KK myoblast group also had reduced mean HbA_1c, cholesterol, insulin and triacylglycerol, and increased adiponectin compared with the KK control and KK fibroblast groups. C57BL mice showed no change in glucose homeostasis after hSkM transplant.

Conclusions/interpretation

Human skeletal myoblast transplantation attenuated hyperglycaemia and hyperinsulinaemia and improved glucose tolerance in the KK mouse. This novel approach of improving muscle insulin resistance may be a potential alternative treatment for type 2 diabetes mellitus.

Available only for authorised users

Mokdad AH, Ford ES, Bowman BA et al (2001) The continuing increase of diabetes in the US. Diabetes Care 24:412PubMedCrossRef

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef

Krone W, Meinertz T (1995) Metabolic syndrome as a cardiovascular risk factor. Herz 20:2–4 (article in German)PubMed

Baudler S, Krone W, Brüning JC (2003) Genetic manipulation of the insulin signalling cascade in mice—potential insight into the pathomechanism of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 17:431–443PubMedCrossRef

Guillausseau PJ, Tielmans D, Virally-Monod M, Assayag M (1997) Diabetes: from phenotypes to genotypes. Diabetes Metab 23:14–21PubMed

Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD (1999) Concordance rate for type 2 diabetes mellitus in monozygotic twins: actuarial analysis. Diabetologia 42:146–150PubMedCrossRef

Stern MP (1999) Genetic and environmental influences on type 2 diabetes mellitus in Mexican Americans. Nutr Rev 57:S66–S70PubMed

Zisman A, Peroni OD, Abel ED et al (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6:924–928PubMedCrossRef

Farese RV, Sajan MP, Yang H et al (2007) Muscle-specific knockout of PKC-λ impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 117:2289–2301PubMedCrossRef

10.

Koh HJ, Arnolds DE, Fujii N et al (2006) Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol 26:8217–8227PubMedCrossRef

11.

Saltiel AR (2001) New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517–529PubMedCrossRef

12.

Mauro A (1961) Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9:493–495PubMedCrossRef

13.

Campion DR (1984) The muscle satellite cell: a review. Int Rev Cytol 87:225–251PubMedCrossRef

14.

Kim J, Wang ZM, Heymsfield SB, Baumgartner RN, Gallagher D (2002) Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr 76:378–383PubMed

15.

Iwatsuka H, Shino A, Suzuoki Z (1970) General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17:23–35PubMed

16.

Ye L, Haider Kh H, Tan RS et al (2007) Transplantation of nanoparticle transfected skeletal myoblasts over-expressing vascular endothelial growth factor-165 for cardiac repair. Circulation 116:I113–I120PubMedCrossRef

17.

Ye L, Haider Kh H, Tan RS et al (2008) Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials 29:2125–2137PubMedCrossRef

18.

Lee KS, Kim SR, Park SJ et al (2006) Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol Pharmacol 69:1829–1839PubMedCrossRef

19.

Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473–486PubMed

20.

Ferrannini E (1997) Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev 13:81–86PubMedCrossRef

21.

Zierath JR, Krook A, Wallberg-Henriksson H (2000) Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821–835PubMedCrossRef

22.

Law PK, Goodwin TG, Fang Q et al (1997) First human myoblast transfer therapy continues to show dystrophin after 6 years. Cell Transplant 6:95–100PubMedCrossRef

23.

Bischoff R, Heintz C (1994) Enhancement of skeletal muscle regeneration. Dev Dyn 201:41–54PubMed

24.

Karpati G, Pouliot Y, Carpenter S (1988) Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23:64–72PubMedCrossRef

25.

Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM (1989) Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337:176–179PubMedCrossRef

26.

Morgan JE, Hoffman EP, Partridge TA (1990) Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111:2437–2449PubMedCrossRef

27.

Morris F, White C, Ronald K (1994) Insulin signaling system. J Biol Chem 269:1–4

28.

Watt DJ, Morgan JE, Partridge TA (1984) Use of mononuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve 7:741–750PubMedCrossRef

29.

Watt DJ, Morgan JE, Clifford MA, Partridge TA (1987) The movement of muscle precursor cells between adjacent regenerating muscles in the mouse. Anat Embryol 175:527–536PubMedCrossRef

30.

Gussoni E, Wang Y, Fraefel C et al (1996) A method to codetect introduced genes and their products in gene therapy protocols. Nat Biotechnol 14:1012–1016PubMedCrossRef

31.

Gussoni E, Blau HM, Kunkel LM (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3:970–977PubMedCrossRef

Title: Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus
Authors: L. Ye
K. O. Lee
L. P. Su
W. C. Toh
H. K. Haider
P. K. Law
W. Zhang
S. P. Chan
E. K. W. Sim
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 9/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1421-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 9/2009

Familial association between type 1 diabetes and other autoimmune and related diseases

Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants?

Does diabetes therapy influence the risk of cancer?

Mitochondrial DNA content in peripheral blood monocytes: relationship with age of diabetes onsetand diabetic complications

Glucose challenge test screening for prediabetes and undiagnosed diabetes

A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page